Protector Training for First RAF Cohort Begins at GA-ASI’s FTTC

MQ-9B Training at FTTC Will Become Benchmark for Future Training

SAN DIEGO, CA / ACCESSWIRE / May 4, 2023 / On May 1, 2023, the Royal Air Force (RAF) began training its first cohort of pilots, sensor operators, and mission intelligence coordinators on operating its new Protector Remotely Piloted Aircraft System (RPAS) at the Flight Test & Training Center (FTTC) in Grand Forks, N.D. The FTTC is owned and operated by General Atomics Aeronautical Systems, Inc. (GA-ASI), which has begun deliveries of Protector RPAS to the RAF. Protector is a derivative of the MQ-9B SkyGuardian® and is initially being flown in the USA for training.

Related Image

GA-ASI is training the first four Operational Conversion Units (OCUs), each comprising eight crews, including pilots, sensor operators (SOs), and mission intelligence coordinators (MICs). Upon completion, the crews will operate the Protector Air system as part of 31, 54 or 56 Sqn. Training for the pilots and SOs is scheduled to run for 12 weeks; six weeks for MICs.

The scope of the training is focused on foundational skills required to operate the Protector air vehicle and its equipment, including the Multi-Spectral Targeting System (MTS), Synthetic Aperture Radar (SAR), Mission Intelligence Station (MIS), and System for Tasking and Real-Time Exploitation (STARE). Training involves building solid foundations for both normal and emergency operations in Intelligence, Surveillance, and Reconnaissance (ISR) systems, instrument flying, and Automatic Takeoff and Landing Capability (ATLC).

The training includes simulation and live flight of the air vehicle. The synthetic training includes a desktop procedural trainer and a mission trainer.

“The training services performed at our Grand Forks center for the RAF represent an important benchmark for future MQ-9B training for other partners,” said GA-ASI President David R. Alexander.

MQ-9B has garnered significant interest from customers throughout the world. After the UK Ministry of Defence selected MQ-9B SkyGuardian for its Protector program, the Belgian Ministry of Defence signed a contract for SkyGuardian. The Japan Coast Guard is currently operating MQ-9B in the SeaGuardian® configuration, which the Japan Maritime Self-Defense Force (JMSDF) also recently selected for its Medium-Altitude, Long-Endurance (MALE) RPAS Trial Operation Project that began in April. Additionally, the U.S. Air Force Special Operations Command (AFSOC) signed a contract for three MQ-9B SkyGuardians, becoming the first U.S. customer for those aircraft.

About GA-ASI

General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable remotely piloted aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than seven million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com.

Avenger, Lynx, Predator, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.

Contact Information

GA-ASI Media Relations
GA-ASI Media Relations
asi-mediarelations@ga-asi.com
+1 (858) 524-8101

SOURCE: General Atomics

Government of India Grants Pan India Unified Licenses to Zoom

Zoom aims to empower the India workforce with the rollout of Zoom Phone

SAN JOSE, Calif., May 04, 2023 (GLOBE NEWSWIRE) — Today, Zoom (NASDAQ: ZM) announced that it has received the Unified License with Access – All/PAN India, NLD National Long Distance, and ILD – International Long Distance from the Department of Telecommunications (DoT), Government of India. With these licenses, the company will be able to offer Zoom Phone, its industry leading cloud PBX service, to multinational corporations (MNCs) and businesses operating in India.

Zoom Phone is a global cloud PBX application service, enabling MNCs and businesses in India to have a single communication platform for their global workforce. Zoom partners with international telecommunication providers and offers phone numbers and calling plans in 47 countries and territories bundled with cloud PBX service, making it simple for customers to deploy and manage their phone services.

Zoom Phone offers a robust set of features for the modern workforce, including intelligent call routing, auto attendants, interactive voice response, shared line appearance, call queuing, call analytics, voicemail, recordings and transcriptions, desktop/mobile app experience optimized for business users and integrations with CRM applications.

“We are thrilled and proud to receive the unified licenses from the Department of Telecommunications. With Zoom Phone, India businesses and multinational corporations can support hybrid work environments, foster greater collaboration among employees and elevate the customer experience,” said Abe Smith, Head of International, Zoom. “This important milestone underscores our continued focus in countries like India, a strategic growth market for Zoom, and our commitment to bringing new and innovative collaboration solutions to our customers.”

Zoom Phone grew more than 100% year over year globally in fiscal year 2023, surpassing 5.5 million seats in the fourth quarter of fiscal year 2023. This is a testament to Zoom Phone’s ability to meet customer requirements for simplicity and flexibility and help businesses transition to a modern cloud communications platform.

In the coming months, Zoom will be working with regulators and partners in India to offer a complete telecommunications service bundled with its Zoom Phone PBX service.

“Feeling the pinch to produce more with less, Indian multinationals are increasingly turning to collaboration platforms including video communications to streamline workflows and engage employees, partners as well as their customers. The launch of Zoom Phone will offer a competitive edge to the collaboration solution vendor in targeting the Indian enterprise customers,” said Nikhil Batra, Research Director, Telecom at IDC. “Collaboration solutions have been highlighted by Indian enterprises as their top ICT investment priority through the course of 2023 and Zoom Phone, along with the broader Zoom collaboration portfolio, could help organizations accelerate this move to support and empower an increasingly mobile and connected workforce.”

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Public Relations
Colleen Rodriguez
Head of Global PR for Zoom
press@zoom.us

GlobeNewswire Distribution ID 8831836

Hitachi Energy, the partner of choice for largest-ever HVDC wind energy project in U.S.

The SunZia Transmission Project, enabled by HVDC Light®, links New Mexico’s wind farms to Arizona’s grid, increasing renewable energy to the Western States.

Zurich, Switzerland, May 04, 2023 (GLOBE NEWSWIRE) — Zurich, Switzerland, May 4, 2023 – Hitachi Energy, a global technology leader that is advancing a sustainable energy future for all, has been selected by Pattern Energy to supply its high-voltage direct current (HVDC) and other advanced technologies for the SunZia Transmission Project. It will connect the 3,500-megawatt (MW) SunZia Wind project in New Mexico to the power grid in Arizona and Southern California, which will be among the world’s largest transmission links delivering renewable energy.

Hitachi Energy’s HVDC Light® technology will efficiently transfer and integrate huge volumes of wind power over more than 885 kilometers (550 miles) into the regional power grid. This will significantly increase the availability of sustainable energy for homes and businesses throughout the region.

When complete, SunZia Wind will have a total power capacity of 3,500 MW, enough clean, renewable electricity to provide power to approximately three million Americans.1 The HVDC link will efficiently transmit up to 3,000 MW of this power west to Arizona. The HVDC Light® system will be the largest voltage source converter (VSC) installation in the United States, one of the largest worldwide, and one of the country’s longest HVDC connections.

“We are proud to be advancing a sustainable energy future for all in the southwestern United States, enabling Pattern Energy to integrate emission-free electricity into the regional grid serving Arizona and Southern California,” said Niklas Persson, Managing Director of Hitachi Energy’s Grid Integration business. “Our market-leading HVDC technologies combined with our execution expertise makes us the partner of choice to help the U.S. achieve its carbon-neutral targets by efficiently and reliably maximizing its renewable energy resources.”

“Our collaboration with Hitachi Energy is an important milestone for the SunZia Transmission Project and will enable us to harness and carry this great energy potential to the areas where there is a high demand for renewable energy,” said Hunter Armistead, CEO of Pattern Energy. “The use of HVDC technology will enhance power grid reliability and resilience and play a vital role in delivering clean energy and deploying a sustainable energy system in the U.S.”

The SunZia Transmission project is a 3,000 MW HVDC link between Corona, New Mexico and Pinal County, Arizona. Hitachi Energy has already started work on designing and engineering the two HVDC Light® converter stations, one at either end of the link. The transmitting station converts the power from AC to DC for transport in the overhead lines, then back to AC for integration into the receiving grid.

Hitachi Energy has partnered with Quanta Services, Inc. (Quanta) to provide a turnkey project solution for the SunZia project, including managing the HVDC construction and building installation at the associated project sites. Quanta is an industry leader providing specialized infrastructure solutions to the utility, renewable energy, communications, pipeline, and energy industries. The collaboration with Quanta is designed to leverage the core competencies of the two companies to deliver a best-in-class solution for the project. The HVDC converter stations are expected to be in-service by the end of 2025 to support final testing and commissioning of the SunZia Wind facilities in 2026.

To find the optimal solution that considers the impact of the new facility on the existing grid, a system study and a comprehensive interconnection and system impact analysis were conducted by Hitachi Energy´s expert consultants.

Hitachi Energy will also supply ‘alternating current (AC) chopper’ technology to help restore power if the power flow on the DC line or in the AC grid in Arizona is temporarily interrupted by weather and other contingency events.

Hitachi Energy has delivered more than half of the HVDC projects in North America. These include the Pacific Intertie transmission system, which transfers electricity from the Pacific Northwest to Los Angeles, the Quebec-New England link, which was the first large-scale multi-terminal HVDC transmission system in the world, and the Maritime link, which connects the Islands of Newfoundland and Nova Scotia, supporting the integration of renewable energy sources and improving grid stability. The company has also recently announced new HVDC projects including Champlain Hudson Power Express, the Châteauguay converter station modernization with Hydro Quebec, and the InterMountain Power Project.2

Note to editors

Hitachi Energy’s HVDC solution combines world-leading expertise in HVDC converter valves, the MACH™ digital control platform3 converter power transformers and high-voltage switchgear, as well as in system studies, design and engineering, supply, installation supervision and commissioning.

HVDC Light® is a voltage source converter technology developed by Hitachi Energy. It is the preferred technology for many grid applications, including interconnecting countries, integrating renewables and “power-from-shore” connections to offshore production facilities. HVDC Light’s defining features include uniquely compact converter stations and exceptionally low electrical losses.

Hitachi Energy pioneered commercial HVDC technology almost 70 years ago and has delivered more than half of the world’s HVDC projects.

https://sunzia.net/impact/
Hitachi Energy HVDC references North America
Modular Advanced Control for HVDC (MACH™)

HVDC website:
https://www.hitachienergy.com/offering/product-and-system/hvdc

                                                                                                                                                – END –

About Hitachi Energy Ltd.
Hitachi Energy is a global technology leader that is advancing a sustainable energy future for all. We serve customers in the utility, industry and infrastructure sectors with innovative solutions and services across the value chain. Together with customers and partners, we pioneer technologies and enable the digital transformation required to accelerate the energy transition towards a carbon-neutral future. We are advancing the world’s energy system to become more sustainable, flexible and secure whilst balancing social, environmental and economic value. Hitachi Energy has a proven track record and unparalleled installed base in more than 140 countries. Headquartered in Switzerland, we employ around 40,000 people in 90 countries and generate business volumes of approximately $10 billion USD.
https://www.hitachienergy.com
https://www.linkedin.com/company/hitachienergy
https://twitter.com/HitachiEnergy

About Hitachi, Ltd.
Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers’ and society’s challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products, under the business structure of Digital Systems & Services, Green Energy & Mobility, Connective Industries and Automotive Systems. Driven by green, digital, and innovation, we aim for growth through collaboration with our customers. The company’s consolidated revenues for fiscal year 2021 (ended March 31, 2022) totaled 10,264.6 billion yen ($84,136 million USD), with 853 consolidated subsidiaries and approximately 370,000 employees worldwide. For more information on Hitachi, please visit the company’s website at https://www.hitachi.com.

Attachments

Jocelyn Chang
Hitachi Energy
jocelyn.chang@hitachienergy.com

GlobeNewswire Distribution ID 8832144

NovaSight CureSight (TM) Wins 2023 MedTech Breakthrough Award

CureSight™ Amblyopia treatment device named “Best New Technology Solution for Ophthalmology” for its innovation, impact, and market potential

LOD, ISRAEL / ACCESSWIRE / May 4, 2023 / NovaSight, a pediatric-focused eyecare MedTech company, announced today that its CureSight binocular digital treatment system for amblyopia (lazy eye) has been named “Best New Technology Solution for Ophthalmology” in the 7th annual MedTech Breakthrough Awards program. The award program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global health and medical technology market.

NovaSight provides pediatric patients with eye-tracking based digital vision care solutions by focusing on three major verticals: treatment, diagnostics, and prevention of visual health impairments.

CureSight is an FDA-cleared and CE marked eye-tracking based amblyopia treatment system, designed to replace the traditional eye patching. The treatment is carried out while the patient watches his favorite streamed content from the comfort of his home. By tracking the gaze position of the dominant eye in real-time, the CureSight system blurs its center of vision, while keeping the rest of the image sharp – and providing the amblyopic eye with a normal, high contrast image. This stimulates the brain to complete the blurred image from the amblyopic eye, improving its acuity and developing stereoacuity as the eyes learn to work together.

“Amblyopia, or what’s known as ‘lazy-eye’ affects three percent of the population and puts the patients at risk for eventual vision loss. The gold standard treatment for lazy eye has so far consisted of placing a patch over the strong eye – an old-fashioned solution which suffers from very low compliance,” said James Johnson, managing director, MedTech Breakthrough. “With the breakthrough of CureSight’s binocular treatment from NovaSight, children develop stereoscopic vision, which is difficult to achieve with the monocular nature of the traditional patching treatment. This breakthrough technology helps to shift treatment into the digital age and we are thrilled to congratulate the NovaSight team for taking home a well-deserved 2023 MedTech Breakthrough Award.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data and many more. This year’s program attracted more than 4,000 nominations from over 17 different countries throughout the world.

“We are proud to be named ‘Best New Technology Solution for Ophthalmology’ acknowledging our mission to prevent vision impairments among pediatric patients by developing solutions that are specifically designed for the unique needs and attention span of children” said Ran Yam, NovaSight co-founder and CEO. “In a recent pivotal trial which was the basis for our FDA approval, we compared the improvement in visual outcomes (visual acuity and stereoacuity) achieved by CureSight versus the traditional eye patch. This is the first ever pivotal trial where a digital device was shown to be non-inferior to eye patching for amblyopia treatment in children. We will continue to strive to change the lives of millions of children by introducing eye tracking based vision care solutions.”

Additionally, the CureSight system is connected to a dedicated cloud platform which allows the physician to monitor treatment progress and compliance remotely. The eye care provider receives a comprehensive patient vision summary, and progress reports and real-time monitoring of the child’s treatment are easily accessible.

CureSight was officially launched in the US and Italy earlier this year with exceptional early adoption by the pediatric ophthalmology community and their patients. Equipped with 3 unique CPT codes in the US assigned by the American Medical Association (AMA) last year, NovaSight is pursuing broad coverage with the aim of making CureSight easily accessible to patients whose future vision and eye health depend on the treatment that they receive in their early years.

About NovaSight
NovaSight is an Israeli MedTech company that focuses on bringing pediatric vision care into the digital age. Founded in 2016, NovaSight has experienced rapid growth by delivering complete end-to-end eye-tracking-based solutions for accurate assessment and treatment of early vision disorders.

NovaSight offers two flagship products, both ideally positioned for remote diagnostics and home treatment: The CureSight™ system is an eye tracking-based treatment for lazy eye designed to replace traditional eye patching. The EyeSwift®PRO system is a comprehensive vision assessment device that accurately and objectively screens for multiple vision impairments within seconds. Additional pipeline products include the TrackSight™ digital solution for myopia (short-sightedness) control, targeted to provide an affordable and accessible solution to help in combating the myopia global epidemic, which is growing at an alarming rate.

NovaSight’s management and advisory board is composed of accomplished executives, physicians, researchers, and key opinion leaders in the field of vision care.

About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.

Related Image

Contact Information

Jenny Goldman 
Marketing manager 
jenny@nova-sight.com 
+972 50 9123235 

SOURCE: NovaSight Ltd.

Envision Pharma Group Appoints Healthcare Industry Expert and Experienced Leader Dr. Jennifer Costello, PharmD, BCPS, CMPP, as Chief Medical Officer

PHILADELPHIA, PA / ACCESSWIRE / May 4, 2023 / Envision Pharma Group (Envision) has appointed Dr. Jennifer Costello, PharmD, BCPS, CMPP, to the role of Chief Medical Officer. Jennifer will be responsible for progressing work across all sectors of Envision’s business, including Technology, Medical, Commercial, Public Affairs, and Value & Access and Data Analytics.

Meg Heim, CEO of Envision Pharma Group, adds, “I am so excited to welcome Jennifer to the Envision team as Chief Medical Officer. Jennifer’s deep expertise in science and commercialization in the life sciences industry, in addition to her extensive pharmaceutical understanding and experience will further support the acceleration of our business expansion, mission, and commitment to our vision as a technology-enabled partner to the life sciences industry.”

Jennifer is an accomplished pharmaceutical and healthcare leader with over 20 years of experience across the healthcare sector. She brings to this role extensive cardiovascular, medical, and patient care-related focused expertise, with a successful track record of leading high-performing cross-matrix teams with global impact.

Prior to joining Envision, Jennifer held multiple leadership roles in global medical affairs and publications, US HEOR publications, and global scientific content. She developed a reputation for leading successful partnerships with cross-functional colleagues, advocacy partners, and academic groups that resulted in building innovative programs that foster healthcare transformation.

Jennifer joins Envision from Bristol Myers Squibb, where she most recently led cardiovascular (CV) patient advocacy across its CV portfolio (early phase assets to marketed products). She drove the development and execution of global and US strategies for a successful launch of a first-in-class CV asset, working across early asset development, commercial, and medical affairs teams. For her work in this space, she was awarded the coveted “Innovation Award” from BMS.

Before joining the pharmaceutical industry, her 16 years of experience as a practicing clinical pharmacist was within the academic medical-teaching hospital. Jennifer served in numerous roles as a pediatric critical care specialist, adult ambulatory clinical care specialist, hospital administrator, and as a Director of Clinical Pharmacy Services. Under a collaborative practice agreement, she also led outpatient care optimization, directly co-managing heart failure, antithrombotic, and diabetic patients.

Jennifer received her PharmD from Northeastern University, completed her ASHP PGY-1 residency at the University of Arizona/University Medical Center, and received her board certification as a pharmacotherapy specialist from the American College of Clinical Pharmacy. She served in adjunct teaching positions with Rutgers University and the University of Florida. She has authored over 50 publications and posters and served as a pharmacy national thought leader within the heart failure, antithrombotic, and diabetes management space.

Jennifer adds, “I am delighted and humbled to join the Envision team during this transformative time. I am looking forward to meeting and working with our Envision family, customers, and partners. This is an exciting period for our industry at large, and I am privileged to build upon our company vision, award-winning technology, and innovation as medical affairs and global healthcare communication leaders.”

About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

Contact Information

Colleen Carter
Associate Director, Communications, Office of the CEO
colleen.carter@envisionpharma.com
1 (508) 505 8856

SOURCE: Envision Pharma Group